Seres Therapeutics Inc. (NASDAQ: MCRB) is -9.82% lower on its value in year-to-date trading and has touched a low of $2.50 and a high of $9.49 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MCRB stock was last observed hovering at around $4.92 in the last trading session, with the day’s gains setting it 0.13% off its average median price target of $12.00 for the next 12 months. It is also 66.33% off the consensus price target high of $15.00 offered by 8 analysts, but current levels are -26.25% lower than the price target low of $4.00 for the same period.
Currently trading at $5.05, the stock is -4.57% and -10.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.27 million and changing 2.64% at the moment leaves the stock -14.94% off its SMA200. MCRB registered 41.46% gain for a year compared to 6-month loss of -25.74%. The firm has a 50-day simple moving average (SMA 50) of $139.31 and a 200-day simple moving average (SMA200) of -$2.84.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The stock witnessed a -22.31% gain in the last 1 month and extending the period to 3 months gives it a -1.17%, and is -0.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.02% over the week and 9.25% over the month.
Seres Therapeutics Inc. (MCRB) has around 431 employees, a market worth around $644.58M and $5.10M in sales. Distance from 52-week low is 102.00% and -46.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-398.20%).
Seres Therapeutics Inc. (MCRB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Seres Therapeutics Inc. (MCRB) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Seres Therapeutics Inc. is expected to release its quarterly report on 08/01/2023.The EPS is expected to shrink by -223.70% this year.
Seres Therapeutics Inc. (MCRB) Top Institutional Holders
The shares outstanding are 125.86M, and float is at 116.29M with Short Float at 10.47%.
Seres Therapeutics Inc. (MCRB) Insider Activity
A total of 3 insider transactions have happened at Seres Therapeutics Inc. (MCRB) in the last six months, with sales accounting for 1 and purchases happening 2 times. The most recent transaction is an insider sale by Ege David S. SEC filings show that Ege David S. sold 7,038 shares of the company’s common stock on Apr 28 at a price of $5.19 per share for a total of $36527.0. Following the sale, the insider now owns 59696.0 shares.
Seres Therapeutics Inc. disclosed in a document filed with the SEC on Oct 31 that Ege David S.sold a total of 5,012 shares of the company’s common stock. The trade occurred on Oct 31 and was made at $7.93 per share for $39745.0. Following the transaction, the insider now directly holds 46734.0 shares of the MCRB stock.
Still, SEC filings show that on Jul 05, Nutritional Health LTP Fund Ge (10% Owner) acquired 8,738,243 shares at an average price of $3.15 for $27.53 million. The insider now directly holds 5,875,711 shares of Seres Therapeutics Inc. (MCRB).
Seres Therapeutics Inc. (MCRB): Who are the competitors?
The company’s main competitors (and peers) include Xencor Inc. (XNCR) that is trading 21.95% up over the past 12 months.